PL3837263T3 - Nowe związki heterocykliczne jako inhibitory lipazy monoacyloglicerolowej - Google Patents
Nowe związki heterocykliczne jako inhibitory lipazy monoacyloglicerolowejInfo
- Publication number
- PL3837263T3 PL3837263T3 PL19755855.4T PL19755855T PL3837263T3 PL 3837263 T3 PL3837263 T3 PL 3837263T3 PL 19755855 T PL19755855 T PL 19755855T PL 3837263 T3 PL3837263 T3 PL 3837263T3
- Authority
- PL
- Poland
- Prior art keywords
- heterocyclic compounds
- lipase inhibitors
- new heterocyclic
- monoacylglycerol lipase
- monoacylglycerol
- Prior art date
Links
- 229940127470 Lipase Inhibitors Drugs 0.000 title 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18188681 | 2018-08-13 | ||
| PCT/EP2019/071520 WO2020035424A1 (en) | 2018-08-13 | 2019-08-12 | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3837263T3 true PL3837263T3 (pl) | 2024-10-14 |
Family
ID=63244467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19755855.4T PL3837263T3 (pl) | 2018-08-13 | 2019-08-12 | Nowe związki heterocykliczne jako inhibitory lipazy monoacyloglicerolowej |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US20200308190A1 (pl) |
| EP (2) | EP3837263B1 (pl) |
| JP (2) | JP7637049B2 (pl) |
| KR (1) | KR102879259B1 (pl) |
| CN (1) | CN112867720A (pl) |
| AR (1) | AR116666A1 (pl) |
| AU (1) | AU2019322538B2 (pl) |
| BR (1) | BR112021002298A2 (pl) |
| CA (1) | CA3104928A1 (pl) |
| CL (1) | CL2021000362A1 (pl) |
| CO (1) | CO2021002382A2 (pl) |
| CR (1) | CR20210077A (pl) |
| DK (1) | DK3837263T3 (pl) |
| ES (1) | ES2986417T3 (pl) |
| FI (1) | FI3837263T3 (pl) |
| HR (1) | HRP20241201T1 (pl) |
| HU (1) | HUE067912T2 (pl) |
| IL (1) | IL279173B2 (pl) |
| LT (1) | LT3837263T (pl) |
| MA (1) | MA53219B1 (pl) |
| MX (1) | MX2021001433A (pl) |
| MY (1) | MY210507A (pl) |
| PE (1) | PE20211089A1 (pl) |
| PH (1) | PH12021500013A1 (pl) |
| PL (1) | PL3837263T3 (pl) |
| PT (1) | PT3837263T (pl) |
| RS (1) | RS65912B1 (pl) |
| RU (1) | RU2769507C1 (pl) |
| SG (1) | SG11202013064WA (pl) |
| SI (1) | SI3837263T1 (pl) |
| TW (1) | TWI812770B (pl) |
| UA (1) | UA127629C2 (pl) |
| WO (1) | WO2020035424A1 (pl) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| US20190292188A1 (en) | 2018-02-27 | 2019-09-26 | Incyte Corporation | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| CN113166153B (zh) | 2018-07-05 | 2024-11-01 | 因赛特公司 | 作为a2a/a2b抑制剂的稠合吡嗪衍生物 |
| EP3837263B1 (en) | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| EP3883936B1 (en) | 2018-11-22 | 2023-07-12 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| US20230090255A1 (en) * | 2019-09-05 | 2023-03-23 | Lunan Pharmaceutical Group Corporation | Magl inhibitor, preparation method therefor and use thereof |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| US11814375B2 (en) * | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| MX2022003023A (es) * | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
| AR120029A1 (es) * | 2019-09-24 | 2022-01-26 | Hoffmann La Roche | Compuestos heterocíclicos |
| CA3152213A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| CR20220148A (es) * | 2019-10-07 | 2022-07-03 | De Shaw Res Llc | Compuestos heterocíclicos de arilmetileno como bloqueadores del canal shaker de potasio kv1.3 |
| BR112022019178A2 (pt) * | 2020-03-26 | 2022-11-01 | Janssen Pharmaceutica Nv | Aminociclobutanos como moduladores da monoacilglicerol lipase |
| MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| WO2024031088A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| EP4665718A1 (en) | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US7544678B2 (en) | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| US7842810B2 (en) | 2005-03-31 | 2010-11-30 | Janssen Pharmaceutica, Nv | Bicyclic pyrazole compounds as antibacterial agents |
| ATE450525T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
| JP5116687B2 (ja) | 2005-11-02 | 2013-01-09 | バイエル・ファルマ・アクチェンゲゼルシャフト | がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤 |
| AU2007217040A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-HT6 receptor affinity |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| CN101796051B (zh) | 2007-03-12 | 2013-11-06 | 细胞内治疗公司 | 与取代的杂环稠合的γ-咔啉的合成 |
| FR2915197B1 (fr) * | 2007-04-18 | 2009-06-12 | Sanofi Aventis Sa | Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique. |
| TW200938542A (en) | 2008-02-01 | 2009-09-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| JP5314123B2 (ja) | 2008-03-31 | 2013-10-16 | シー アンド シー リサーチ ラボラトリーズ | 複素環誘導体 |
| MX2011003951A (es) | 2008-10-29 | 2011-05-03 | Hoffmann La Roche | Nuevos derivados de fenilamida o de piridilamida y su uso como agonistas de receptor acoplado a proteina g (gpbar1). |
| RU2538204C2 (ru) | 2009-09-10 | 2015-01-10 | Ф.Хоффманн-Ля Рош Аг | Ингибиторы jak |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US9051296B2 (en) * | 2009-11-16 | 2015-06-09 | Raqualia Pharma Inc. | Aryl carboxamide derivatives as TTX-S blockers |
| US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| WO2013059118A1 (en) | 2011-10-19 | 2013-04-25 | The Trustees Of Columbia University In The City Of New York | Cyclopropenimine catalyst compositions and processes |
| CN103958525A (zh) | 2011-11-30 | 2014-07-30 | 埃科特莱茵药品有限公司 | 3,7-二取代八氢-2H-吡啶并[4,3-e][1,3]噁嗪-2-酮抗生素 |
| IN2014CN04174A (pl) | 2011-12-22 | 2015-09-04 | Novartis Ag | |
| ES2793148T3 (es) | 2012-01-06 | 2020-11-13 | Lundbeck La Jolla Research Center Inc | Compuestos de carbamato y métodos para fabricarlos y usarlos |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| TW201422625A (zh) | 2012-11-26 | 2014-06-16 | Novartis Ag | 二氫－吡啶并－□衍生物之固體形式 |
| TWI644671B (zh) | 2013-03-14 | 2018-12-21 | 比利時商健生藥品公司 | Ｐ２ｘ７調節劑 |
| ES2640482T3 (es) | 2013-04-16 | 2017-11-03 | Idorsia Pharmaceuticals Ltd | Derivados biaromáticos antibacterianos |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| EP3279191B1 (en) * | 2015-03-30 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| EP3294729A1 (en) | 2015-05-13 | 2018-03-21 | Selvita S.A. | Substituted quinoxaline derivatives |
| AU2016264958B2 (en) | 2015-05-21 | 2020-10-29 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
| US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| UA121775C2 (uk) | 2015-07-31 | 2020-07-27 | Пфайзер Інк. | 1,1,1-трифтор-3-гідроксипропан-2-ілкарбаматні похідні та 1,1,1-трифтор-4-гідроксибутан-2-ілкарбаматні похідні як інгібітори magl |
| US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
| US10385057B2 (en) | 2015-11-20 | 2019-08-20 | Lundbeck La Jolla Research Center, Inc. | Pyrazole compounds and methods of making and using same |
| JP6832342B2 (ja) * | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
| EA036637B1 (ru) | 2016-03-31 | 2020-12-02 | Такеда Фармасьютикал Компани Лимитед | Гетероциклические спиросоединения, ингибирующие моноацилглицерин-липазу |
| KR20190022728A (ko) | 2016-06-30 | 2019-03-06 | 바실리어 파마슈티카 인터내셔널 리미티드 | 증식 장애의 치료를 위한 미토콘드리아 억제제 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3541807B1 (en) | 2016-11-16 | 2021-09-29 | H. Lundbeck A/S | A crystalline form of a magl inhibitor |
| PE20200340A1 (es) | 2017-06-12 | 2020-02-14 | Boehringer Ingelheim Int | Compuestos heteroaromaticos como inhibidores de vanina |
| EP3689879B1 (en) | 2017-09-29 | 2025-02-12 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| TW201930300A (zh) | 2017-12-15 | 2019-08-01 | 瑞士商赫孚孟拉羅股份公司 | 新雜環化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| HRP20230388T1 (hr) * | 2018-03-22 | 2023-06-23 | F. Hoffmann - La Roche Ag | Inhibitori oksazin monoacilglicerol lipaze (magl) |
| JP2021533093A (ja) | 2018-08-13 | 2021-12-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | モノアシルグリセロールリパーゼ阻害剤としての新規複素環化合物 |
| EP3837263B1 (en) | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| CN113227068B (zh) | 2018-11-22 | 2023-06-13 | 上海齐鲁锐格医药研发有限公司 | Glp-1r激动剂及其用途 |
| EP3883936B1 (en) | 2018-11-22 | 2023-07-12 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| CN113767105A (zh) | 2019-04-09 | 2021-12-07 | 豪夫迈·罗氏有限公司 | 作为单酰基甘油脂肪酶(magl)的抑制剂的杂环化合物 |
| JP7669299B2 (ja) | 2019-07-03 | 2025-04-28 | エフ． ホフマン－ラ ロシュ アーゲー | 複素環モノアシルグリセロールリパーゼ（ｍａｇｌ）阻害剤 |
| JP7649283B2 (ja) | 2019-07-09 | 2025-03-19 | エフ． ホフマン－ラ ロシュ アーゲー | 新規複素環化合物 |
| US20210094971A1 (en) | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| CN114650994A (zh) | 2019-09-12 | 2022-06-21 | 豪夫迈·罗氏有限公司 | 放射性标记的化合物 |
| US11814375B2 (en) | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| MX2022003023A (es) | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
| AR120029A1 (es) | 2019-09-24 | 2022-01-26 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP4034602A1 (en) | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | Fluorescent probes for monoacylglycerol lipase (magl) |
| CA3152213A1 (en) | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| WO2022043284A1 (en) | 2020-08-26 | 2022-03-03 | F. Hoffmann-La Roche Ag | Heterocyclic compounds useful as magl inhibitors |
| MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
| JP2024521618A (ja) | 2021-04-23 | 2024-06-04 | エフ． ホフマン－ラ ロシュ アーゲー | 複素環式化合物 |
-
2019
- 2019-08-12 EP EP19755855.4A patent/EP3837263B1/en active Active
- 2019-08-12 BR BR112021002298-8A patent/BR112021002298A2/pt unknown
- 2019-08-12 RS RS20240963A patent/RS65912B1/sr unknown
- 2019-08-12 CA CA3104928A patent/CA3104928A1/en active Pending
- 2019-08-12 SG SG11202013064WA patent/SG11202013064WA/en unknown
- 2019-08-12 PE PE2021000135A patent/PE20211089A1/es unknown
- 2019-08-12 PT PT197558554T patent/PT3837263T/pt unknown
- 2019-08-12 CN CN201980053749.3A patent/CN112867720A/zh active Pending
- 2019-08-12 PL PL19755855.4T patent/PL3837263T3/pl unknown
- 2019-08-12 EP EP24183419.1A patent/EP4474017A3/en active Pending
- 2019-08-12 SI SI201930813T patent/SI3837263T1/sl unknown
- 2019-08-12 JP JP2021507457A patent/JP7637049B2/ja active Active
- 2019-08-12 LT LTEPPCT/EP2019/071520T patent/LT3837263T/lt unknown
- 2019-08-12 FI FIEP19755855.4T patent/FI3837263T3/fi active
- 2019-08-12 HR HRP20241201TT patent/HRP20241201T1/hr unknown
- 2019-08-12 CR CR20210077A patent/CR20210077A/es unknown
- 2019-08-12 IL IL279173A patent/IL279173B2/en unknown
- 2019-08-12 WO PCT/EP2019/071520 patent/WO2020035424A1/en not_active Ceased
- 2019-08-12 DK DK19755855.4T patent/DK3837263T3/da active
- 2019-08-12 KR KR1020217004221A patent/KR102879259B1/ko active Active
- 2019-08-12 UA UAA202101016A patent/UA127629C2/uk unknown
- 2019-08-12 HU HUE19755855A patent/HUE067912T2/hu unknown
- 2019-08-12 RU RU2021106145A patent/RU2769507C1/ru active
- 2019-08-12 AU AU2019322538A patent/AU2019322538B2/en active Active
- 2019-08-12 ES ES19755855T patent/ES2986417T3/es active Active
- 2019-08-12 MA MA53219A patent/MA53219B1/fr unknown
- 2019-08-12 MX MX2021001433A patent/MX2021001433A/es unknown
- 2019-08-12 MY MYPI2021000157A patent/MY210507A/en unknown
- 2019-08-13 AR ARP190102303A patent/AR116666A1/es unknown
- 2019-08-13 TW TW108128734A patent/TWI812770B/zh active
-
2020
- 2020-04-09 US US16/844,262 patent/US20200308190A1/en not_active Abandoned
-
2021
- 2021-02-10 CL CL2021000362A patent/CL2021000362A1/es unknown
- 2021-02-11 PH PH12021500013A patent/PH12021500013A1/en unknown
- 2021-02-24 CO CONC2021/0002382A patent/CO2021002382A2/es unknown
-
2022
- 2022-05-20 US US17/749,496 patent/US11802133B2/en active Active
-
2023
- 2023-09-26 US US18/475,065 patent/US12281124B2/en active Active
-
2024
- 2024-09-06 JP JP2024153990A patent/JP2024174966A/ja active Pending
-
2025
- 2025-02-28 US US19/066,414 patent/US20260022130A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279173A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL280762A (en) | Heterocyclic compounds as monoacylglycerol lipase inhibitors | |
| IL276509A (en) | Heterocyclic compounds as kinase inhibitors | |
| ZA202003778B (en) | Heterocyclic compounds as prmt5 inhibitors | |
| IL290508A (en) | Heterocyclic compounds as kinase inhibitors | |
| SG11202104206SA (en) | New heterocyclic compounds | |
| EP3720495A4 (en) | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | |
| IL287767A (en) | cdk inhibitors | |
| IL289594A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| IL289439A (en) | Heterocyclic compounds as bet inhibitors | |
| IL288936A (en) | Heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| IL282659A (en) | Heterocyclic compounds as bet inhibitors | |
| IL289389A (en) | Heterocyclic compounds as kinase inhibitors | |
| IL289617A (en) | Heterocyclic compounds | |
| IL289595A (en) | Heterocyclic compounds | |
| SG11202013016YA (en) | Heterocyclic compounds as trk inhibitors | |
| IL288987A (en) | New heterocyclic compounds | |
| IL289778A (en) | enzyme inhibitors | |
| IL289023A (en) | Bicyclic heterocyclic compounds as inhibitors of bcdin3d activity | |
| EP3947369A4 (en) | HETEROCYCLIC COMPOUNDS AS BCR-ABL INHIBITORS | |
| IL277869A (en) | Substituted propanamides as nuclease inhibitors | |
| EP3976038A4 (en) | HETEROCYCLIC COMPOUNDS AS PRMT5 INHIBITORS | |
| GB201915191D0 (en) | Novel heterocyclic compounds | |
| HK40070024A (en) | Bicyclic heterocyclic compounds as inhibitors ofbcdin3d activity | |
| HK40042815A (en) | Heterocyclic compounds as kinase inhibitors |